Keudell Morrison Wealth Management Reduces Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Keudell Morrison Wealth Management lowered its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 32.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,830 shares of the company’s stock after selling 2,275 shares during the quarter. Keudell Morrison Wealth Management’s holdings in Kymera Therapeutics were worth $229,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Bayesian Capital Management LP purchased a new position in Kymera Therapeutics during the first quarter worth about $569,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Kymera Therapeutics by 18.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock valued at $254,548,000 after purchasing an additional 996,300 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Kymera Therapeutics by 19.3% in the second quarter. Bank of New York Mellon Corp now owns 156,211 shares of the company’s stock valued at $4,663,000 after purchasing an additional 25,317 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Kymera Therapeutics in the second quarter valued at approximately $4,271,000. Finally, E Fund Management Co. Ltd. boosted its stake in shares of Kymera Therapeutics by 391.2% in the second quarter. E Fund Management Co. Ltd. now owns 48,946 shares of the company’s stock valued at $1,461,000 after purchasing an additional 38,981 shares during the period.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $49.86 on Friday. The firm’s fifty day moving average price is $46.98 and its 200 day moving average price is $40.99. Kymera Therapeutics, Inc. has a 1-year low of $13.85 and a 1-year high of $53.27. The firm has a market cap of $3.23 billion, a price-to-earnings ratio of -21.73 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. During the same period last year, the firm posted ($0.90) EPS. Kymera Therapeutics’s quarterly revenue was down 20.9% on a year-over-year basis. As a group, analysts expect that Kymera Therapeutics, Inc. will post -2.83 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $49.10, for a total transaction of $245,500.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $49.10, for a total transaction of $245,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The disclosure for this sale can be found here. Insiders own 15.82% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on KYMR shares. Wolfe Research raised shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a report on Monday, August 26th. Leerink Partnrs raised shares of Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Morgan Stanley raised their target price on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Wednesday. Guggenheim raised their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a report on Friday, November 1st. Finally, Truist Financial reissued a “buy” rating and set a $53.00 price objective (down previously from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Four analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $51.21.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.